The drug price crisis and what outcomes-based contracting can do about it

Melonie Warfel, vice president and general manager for life sciences at software company Model N, provides an Expert View column on pharma's hottest topic.

We have a drug pricing problem in America. Patients want more affordable prescriptions and manufacturers want the best possible return on their significant research and development investments.

Bridging this gap isn’t as simple as changing the list price. Lurking in the background of drug pricing is a complicated process involving: manufacturers, pharmacy benefit managers (PBMs), pharmacies, payers, providers, distributors and the government. Taking on drug pricing requires working with all of these parties and their differing priorities. A daunting task without a simple solution.